Markets
JPMorgan Resumes Denali Therapeutics Coverage With Overweight: What Traders Need to Know
JPMorgan has resumed coverage of Denali Therapeutics with an Overweight rating, sending a bullish signal into a biotech sector already navigating a complex macro backdrop. Here is the full breakdown of what the call means, where DNLI trades technically, and how to frame the risk.